[
  {
    "ts": null,
    "headline": "Relative Strength Soars On Medtronic Stock. Here's How To Get Bullish",
    "summary": "Medtronic stock jumped 2% on Monday as it broke out to a 52-week high and is showing signs of strong accumulation.  Medtronic stock recently received an RS Rating upgrade from 67 to 82 making it a great stock to consider for a bullish option trade.  A bull call spread involves buying a call and then selling a further out-of-the-money call.",
    "url": "https://finnhub.io/api/news?id=bd49ab4d2c214f8f07f1023ab6965ca986677e6852777cacac4d1bb988ab0a07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764099696,
      "headline": "Relative Strength Soars On Medtronic Stock. Here's How To Get Bullish",
      "id": 137611463,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic stock jumped 2% on Monday as it broke out to a 52-week high and is showing signs of strong accumulation.  Medtronic stock recently received an RS Rating upgrade from 67 to 82 making it a great stock to consider for a bullish option trade.  A bull call spread involves buying a call and then selling a further out-of-the-money call.",
      "url": "https://finnhub.io/api/news?id=bd49ab4d2c214f8f07f1023ab6965ca986677e6852777cacac4d1bb988ab0a07"
    }
  },
  {
    "ts": null,
    "headline": "Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall",
    "summary": "A report higher Q4 revenues and lifts its 2026 outlook, yet the stock slips as margins narrow across key business segments.",
    "url": "https://finnhub.io/api/news?id=9af124b3a33de333ce846bb096696b562cd8999b5661146067a979b3b50b5c6d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764092520,
      "headline": "Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall",
      "id": 137606205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "A report higher Q4 revenues and lifts its 2026 outlook, yet the stock slips as margins narrow across key business segments.",
      "url": "https://finnhub.io/api/news?id=9af124b3a33de333ce846bb096696b562cd8999b5661146067a979b3b50b5c6d"
    }
  },
  {
    "ts": null,
    "headline": "How the Narrative Around Medtronic Is Shifting With Analyst Upgrades and New Product Wins",
    "summary": "Medtronic stock has recently seen its fair value price target raised to $109.82 per share, up from $101.13. This change reflects improved analyst sentiment. The upward revision, combined with a slightly lower discount rate, is largely attributed to the company's robust revenue growth projections and continued operational strength. Stay tuned to discover the key drivers behind these changes and how you can keep up with the evolving narrative around Medtronic’s outlook. Analyst Price Targets...",
    "url": "https://finnhub.io/api/news?id=3f76df90d8db39292f7c332f3e14787c5869a590820befe11c3f2b4dad3ecdf4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764058299,
      "headline": "How the Narrative Around Medtronic Is Shifting With Analyst Upgrades and New Product Wins",
      "id": 137601641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic stock has recently seen its fair value price target raised to $109.82 per share, up from $101.13. This change reflects improved analyst sentiment. The upward revision, combined with a slightly lower discount rate, is largely attributed to the company's robust revenue growth projections and continued operational strength. Stay tuned to discover the key drivers behind these changes and how you can keep up with the evolving narrative around Medtronic’s outlook. Analyst Price Targets...",
      "url": "https://finnhub.io/api/news?id=3f76df90d8db39292f7c332f3e14787c5869a590820befe11c3f2b4dad3ecdf4"
    }
  },
  {
    "ts": null,
    "headline": "Indian MedTech Company Makes a Global Mark at PCR London Valves 2025",
    "summary": "Underscoring India's rising influence in global cardiovascular innovation, Meril Life Sciences presented the one-year outcomes from the pivotal LANDMARK Randomized Controlled Trial (RCT) during the Late-Breaking Trial sessions at PCR London Valves 2025, one of the world's most respected structural heart conferences. This milestone marks a significant moment for Indian MedTech, as the indigenous, balloon-expandable Myval THV series is directly compared with leading international transcatheter val",
    "url": "https://finnhub.io/api/news?id=21b983a6a72956588f82f2a00fb778672dee3b4ec72599352cd1af07a19ff67d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764041400,
      "headline": "Indian MedTech Company Makes a Global Mark at PCR London Valves 2025",
      "id": 137601642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Underscoring India's rising influence in global cardiovascular innovation, Meril Life Sciences presented the one-year outcomes from the pivotal LANDMARK Randomized Controlled Trial (RCT) during the Late-Breaking Trial sessions at PCR London Valves 2025, one of the world's most respected structural heart conferences. This milestone marks a significant moment for Indian MedTech, as the indigenous, balloon-expandable Myval THV series is directly compared with leading international transcatheter val",
      "url": "https://finnhub.io/api/news?id=21b983a6a72956588f82f2a00fb778672dee3b4ec72599352cd1af07a19ff67d"
    }
  }
]